<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01458717</url>
  </required_header>
  <id_info>
    <org_study_id>BorderlinePancreas</org_study_id>
    <nct_id>NCT01458717</nct_id>
  </id_info>
  <brief_title>Neoadjuvant Chemoradiation in Patients With Borderline Resectable Pancreatic Cancer</brief_title>
  <official_title>Multicenter Prospective Randomized Phase II/III Study of Neoadjuvant Chemoradiation With Gemcitabine in Patients With Borderline Resectable Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Previous reports suggest benefit of neoadjuvant chemoradiation treatment for borderline&#xD;
      resectable pancreas cancer. This study is a multicenter prospective randomized phase II/III&#xD;
      study of neoadjuvant chemoradiation with gemcitabine in patients with borderline resectable&#xD;
      pancreas cancer. The study is designed in 2 arms, one with upfront surgery and the other with&#xD;
      neoadjuvant chemoradiation therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Previous reports suggest benefit of neoadjuvant chemoradiation treatment for borderline&#xD;
      resectable pancreas cancer.&#xD;
&#xD;
      This study is a multicenter prospective randomized phase II/III study of neoadjuvant&#xD;
      chemoradiation with gemcitabine in patients with borderline resectable pancreas cancer. The&#xD;
      study is designed in 2 arms, one with upfront surgery and the other with neoadjuvant&#xD;
      chemoradiation therapy.&#xD;
&#xD;
      This phase 2/3 multicenter randomized controlled trial was designed to enroll 110 patients&#xD;
      with BRPC who were randomly assigned to gemcitabine-based neoadjuvant chemoradiation&#xD;
      treatment (54 Gray external beam radiation) followed by surgery or upfront surgery followed&#xD;
      by chemoradiation treatment from four large-volume centers in Korea. The primary endpoint was&#xD;
      the 2-year survival rate (2-YSR). Interim analysis was planned at the time of 50% case&#xD;
      enrollment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">January 2018</completion_date>
  <primary_completion_date type="Actual">January 2018</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>2-year survival rate</measure>
    <time_frame>2-year actual survival outcome</time_frame>
    <description>2-year actual survival outcome</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Median survival</measure>
    <time_frame>after at least of 2-years follow up of all participants</time_frame>
    <description>calculated from overall survival with Kaplan-Meier method</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>1-year survival rate</measure>
    <time_frame>after at least of 1-year follow up of all participants</time_frame>
    <description>1-year actual survival rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>R0 resection rate</measure>
    <time_frame>within 3 weeks after operation</time_frame>
    <description>according to pathology report after operation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>curative resection rate</measure>
    <time_frame>within 3 weeks after operation</time_frame>
    <description>according to pathology report after operation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>local recurrence</measure>
    <time_frame>within at least 2-years follow up</time_frame>
    <description>any point during the follow-up period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>response rate after neoadjuvant chemoradiation</measure>
    <time_frame>within 6 weeks after completion of neoadjuvant chemoradiation</time_frame>
    <description>comparison of imaging study findings at pre- and post-neoadjuvant chemoradiation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>efficacy of imaging study after neoadjuvant chemoradiation</measure>
    <time_frame>within 3 weeks after operation</time_frame>
    <description>comparison of pathology report and imaging study in patients who completed neoadjuvant chemoradiation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">58</enrollment>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>Neoadjuvant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Neoadjuvant - operation - maintenance chemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Upfront surgery</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Operation - adjuvant chemoradiation - maintenance chemotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neoadjuvant chemoradiation</intervention_name>
    <description>Neoadjuvant chemoradiation; 45Gy/25fx + 9Gy/5fx of radiation over 6 weeks with Gemcitabine 400mg/㎡&#xD;
4 weeks rest, re-evaluation for resectability&#xD;
operation&#xD;
start maintenance chemotherapy within 4~6 weeks after operation with Gemcitabine 1000mg/㎡ (D1, 8, 15) every 4 weeks, for 4 cycle</description>
    <arm_group_label>Neoadjuvant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Upfront surgery</intervention_name>
    <description>Operation at time of diagnosis&#xD;
Adjuvant chemoradiation; 45Gy/25fx + 9Gy/5fx of radiation over 6 weeks with Gemcitabine 400mg/㎡&#xD;
start maintenance chemotherapy within 4~6 weeks after completion of adjuvant chemoradiation with Gemcitabine 1000mg/㎡ (D1, 8, 15) every 4 weeks, for 4 cycle</description>
    <arm_group_label>Upfront surgery</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  &gt;18 years old or &lt;75 years old&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
          -  biopsy proven adenocarcinoma of the pancreas&#xD;
&#xD;
          -  no history of previous chemotherapy&#xD;
&#xD;
          -  borderline resectable pancreas cancer&#xD;
&#xD;
          -  no distant metastasis&#xD;
&#xD;
          -  WBC at least 3,000/mm3 or absolute neutrophil count at least 1,500/mm3, Platelet count&#xD;
             at least 125,000/mm3&#xD;
&#xD;
          -  Bilirubin less than 2.5 mg/dL AST less than 5 times upper limit of normal&#xD;
&#xD;
          -  Creatinine no greater than 1.5 times upper limit of normal&#xD;
&#xD;
          -  informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  history of previous chemotherapy&#xD;
&#xD;
          -  history of radiation at &gt;25% area of bone marrow&#xD;
&#xD;
          -  stage unspecified, with distant metastasis, recurrent pancreas cancer&#xD;
&#xD;
          -  history of malignant neoplasm (except stage 0 cancer, skin in situ cancer except&#xD;
             malignant melanoma). Patients who are NED after 5 years after treatment of malignant&#xD;
             neoplasm can be candidate of this study&#xD;
&#xD;
          -  pregnant, breast-feeding patient&#xD;
&#xD;
          -  uncontrolled or active infection&#xD;
&#xD;
          -  uncontrolled cardiopulmonary disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jin-Young Jang, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University College of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Center for Liver Cancer, National Cancer Center</name>
      <address>
        <city>Goyang</city>
        <state>Gyeonggi</state>
        <zip>410-769</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam</city>
        <zip>463-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gangnam Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <study_first_submitted>October 19, 2011</study_first_submitted>
  <study_first_submitted_qc>October 24, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 25, 2011</study_first_posted>
  <last_update_submitted>April 30, 2018</last_update_submitted>
  <last_update_submitted_qc>April 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Jin-Young Jang</investigator_full_name>
    <investigator_title>Associate professor</investigator_title>
  </responsible_party>
  <keyword>pancreas</keyword>
  <keyword>cancer</keyword>
  <keyword>borderline resectable</keyword>
  <keyword>locally advanced</keyword>
  <keyword>resectability</keyword>
  <keyword>chemotherapy</keyword>
  <keyword>radiation</keyword>
  <keyword>chemoradiation</keyword>
  <keyword>neoadjuvant</keyword>
  <keyword>survival</keyword>
  <keyword>prognosis</keyword>
  <keyword>recurrence</keyword>
  <keyword>response rate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

